Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Oncology Panel 150

AltheaDx has received CLIA validation for a next-generation sequencing panel for its pharma services program. The AltheaDx Oncology Panel 150 (AOP 150) is a targeted, NGS assay for drug and companion diagnostic development programs, and simultaneously tests 143 solid tumor genes. The panel is based on Thermo Fisher Scientific's Oncomine Comprehensive Assay and runs on the Ion Torrent NGS platform. It s designed to work with minimal sample input per run and is well-suited for analysis of tumor samples extracted from formalin-fixed paraffin-embedded tissue, including small biopsies and fine needle aspirates, AltheaDx said.